Drug Profile
Research programme: anti-infective therapeutics - Redx Pharma/Royal Liverpool and Broadgreen University Hospitals NHS Trust
Alternative Names: Antibacterials - Redx Pharma/Royal Liverpool and Broadgreen University Hospitals NHS Trust; Antibiotics - Redx Pharma/Royal Liverpool and Broadgreen University Hospitals NHS TrustLatest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Redx Pharma
- Developer Redx Pharma; Royal Liverpool and Broadgreen University Hospitals NHS Trust
- Class Anti-infectives; Antibacterials
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections